CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 63.10% | 145.23% | 136.17% | 60.39% | 83.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.10% | 115.72% | 98.35% | 77.13% | 94.83% |
| Operating Income | -74.10% | -115.72% | -98.35% | -77.13% | -94.83% |
| Income Before Tax | -58.57% | -16.22% | -82.75% | -79.15% | -229.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.57% | -16.22% | -66.73% | -56.36% | -156.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.57% | -16.22% | -66.73% | -56.36% | -156.83% |
| EBIT | -74.10% | -115.72% | -98.35% | -77.13% | -94.83% |
| EBITDA | -78.44% | -123.60% | -144.43% | -157.48% | -294.47% |
| EPS Basic | -168.04% | -334.46% | -191.83% | -116.64% | -111.57% |
| Normalized Basic EPS | -276.68% | -- | -306.99% | -194.19% | -265.68% |
| EPS Diluted | -168.04% | -334.46% | -191.83% | -116.64% | -111.57% |
| Normalized Diluted EPS | -276.68% | -- | -306.99% | -194.19% | -265.68% |
| Average Basic Shares Outstanding | 14,215.30% | -- | 153.40% | -91.80% | -94.61% |
| Average Diluted Shares Outstanding | 1,039.40% | 187.18% | -32.36% | -67.18% | -48.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |